| Budget Amount *help |
¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2013: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2012: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2011: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Research Abstract |
Antigen-specific T cells play a central role for protecting a host against various type of pathogen including neoplastic tumor and viral infections. There are many cell therapeutic approaches using ex vivo expanded immune cells including antigen-specific T cells of cancer or chronic viral infection patients, however, expansion related T-cell senescence causes severe decrease of therapeutic efficacy. To overcome the problem, we have focused on iPS cells as source of antigen specific T cells and successfully we have developed a method to obtain rejuvenated CD8 single positive T cells preserving antigen-specificity of original T cells by using of plurypotent reprogramming technology. Such rejuvenated CD8 T cells were revealed to have enough function as cytotoxic T cells (Nishimura T et al., Cell Stem Cell 12;114-126, 2013).
|
